Basilea Pharmaceutica AG
SIX:BSLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Repco Home Finance Ltd
NSE:REPCOHOME
|
IN |
Basilea Pharmaceutica AG
Total Equity
Basilea Pharmaceutica AG
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Equity
CHf127.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Equity
-$185.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Equity
$1.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
49%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Equity
-CHf1.1B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Equity
CHf76.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Equity
CHf32.6m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
See Also
What is Basilea Pharmaceutica AG's Total Equity?
Total Equity
127.9m
CHF
Based on the financial report for Dec 31, 2025, Basilea Pharmaceutica AG's Total Equity amounts to 127.9m CHF.
What is Basilea Pharmaceutica AG's Total Equity growth rate?
Total Equity CAGR 10Y
24%
Over the last year, the Total Equity growth was 58%.
